Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomised, Open-label, Multicenter International Trial Comparing Ruxolitinib With Either HydRoxycarbamIDe or Interferon Alpha as First Line ThErapy for High Risk Polycythemia Vera

NCT04116502 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.

NCT NCT04116502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04116502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomised, Open-label, Multicenter International Trial Comparing Ruxolitinib With Either HydRoxycarbamIDe or Interferon Alpha as First Line ThErapy for High Risk Polycythemia Vera
Lead sponsor
University of Birmingham
Phase
Phase 3
Overall status
Recruiting
Start date
October 25, 2019
Completion date
April 1, 2030
Enrollment
586 (estimated)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

polycythemia vera